MRTX - Mirati Therapeutics Inc Stock Price, Fair Value and News

$58.70

Market Closed

MRTX Stock Valuation Analysis

Valuation

Max Portfolio %

MRTX Price Action

MRTX RSI Chart

MRTX Stock Valuation Analysis

Valuation

Max Portfolio %

MRTX Valuation

MRTX Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

MRTX Fundamentals

MRTX Revenue

MRTX Earnings

MRTX Profitability

MRTX Investor Care

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	18.9M	27.2M	38.2M	0
2022	67.0M	48.8M	30.6M	12.4M
2021	0	0	49.3M	85.2M
2020	5.9M	8.4M	10.9M	13.4M
2019	4.7M	5.3M	6.3M	3.3M
2018	5.6M	8.0M	10.5M	12.9M
2011	0	0	0	3.1M

Get all data in R, Python etc through our Historical Stock Data APIs

About Mirati Therapeutics Inc

Mirati Therapeutics, Inc., a commercial-stage oncology company, develops novel therapeutics to address the genetic and immunological promoters of cancer in the United States. The company provides KRAZATI, an oral targeted treatment option for adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung (NSCLC), as well as in clinical development as a monotherapy and in combination with other agents. It also develops Sitravatinib, an investigational spectrum-selective kinase inhibitor in Phase 3 clinical development that inhibits receptor tyrosine kinases (RTKs), including TAM family receptors, split family receptors, and RET, which overcomes resistance to checkpoint inhibitor therapy through targeted reversal of an immunosuppressive tumor microenvironment that enhances antigen-specific T cell response and expanding dendritic cell-dependent antigen presentation. In addition, the company pipeline comprises the MRTX1719, an investigational synthetic lethal PRMT5 inhibitor designed to target the PRMT5/methylthioadensoine (MTA) complex and is in clinical development; MRTX0902, a selective SOS1 inhibitor that improves anti-tumor efficacy in combination with targeted mitogen-activated protein kinase (MAPK)-pathway inhibitors, and is in clinical development; and MRTX1133, an investigational lead KRAS G12D compound. It has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib; and Zai Lab Ltd. to research, develop, manufacture, and commercialize adagrasib in various indications. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.

CEO	Dr. Charles M. Baum M.D., Ph.D.
WEBSITE	mirati.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	587